Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02890069 · ClinicalTrials.gov registry record · Phase 1
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
A Phase 1 study of Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 298
- Enrollment target
- 20
- Study locations
NCT02890069 is a Phase 1 study of Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 298 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT02890069, a Phase 1 study of Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 298 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study was to combine the PDR001 checkpoint inhibitor with several agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations.
Conditions Studied
Interventions
- DRUG Everolimus
- DRUG Panobinostat
- BIOLOGICAL PDR001
- DRUG LCL161
- DRUG QBM076
Study Locations (20)
Other
- Novartis Investigative Site - Jena
- Novartis Investigative Site - Ulm
- Novartis Investigative Site - Würzburg
- Novartis Investigative Site - Amsterdam
- Novartis Investigative Site - Leiden
- Novartis Investigative Site - Rotterdam
- Novartis Investigative Site - Utrecht
- Novartis Investigative Site - Seoul
Texas
- University of Texas MD Anderson Cancer Center - Houston
- UT Health San Antonio Mays Cancer Center - San Antonio
California
- UCLA Santa Monica Hematology / Oncology SC - Santa Monica
Maryland
- Sidney Kimmel Comprehensive Cancer Center - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- The Regents of the University of Michigan - Ann Arbor
Missouri
- Washington University Medical School SC - St Louis
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 298 participants |
| Start Date | 2016-10-14 |
| Est. Completion | 2022-02-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02890069
The ClinicalTrials.gov registry entry for NCT02890069 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 298 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Everolimus is the first listed.
NCT02890069 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Texas, California.
Frequently Asked Questions
What is clinical trial NCT02890069 about?
NCT02890069 is a clinical study titled "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat". The purpose of this study was to combine the PDR001 checkpoint inhibitor with several agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations.
What is the current status of trial NCT02890069?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 298 participants. The study started on 2016-10-14. Estimated completion is 2022-02-22.
What conditions does trial NCT02890069 study?
This clinical trial studies the following conditions: Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma.
What interventions are being tested in trial NCT02890069?
The interventions under investigation include: Everolimus (DRUG), Panobinostat (DRUG), PDR001 (BIOLOGICAL), LCL161 (DRUG), QBM076 (DRUG).
Who is sponsoring clinical trial NCT02890069?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02890069 being conducted?
This trial has 20 study locations across California, Maryland, Massachusetts, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.